ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Washington University School of Medicine
Washington University School of Medicine
Hummingbird Bioscience
Bristol-Myers Squibb
Janssen Research & Development, LLC
Amgen
Shanghai JMT-Bio Inc.
Hoffmann-La Roche
Krystal Biotech, Inc.
Dizal Pharmaceuticals
NuCana plc
OncoC4, Inc.
Karyopharm Therapeutics Inc
Bristol-Myers Squibb
Genprex, Inc.
Phanes Therapeutics
GlaxoSmithKline
Shanghai Chest Hospital
University of Texas Southwestern Medical Center
Bristol-Myers Squibb
OncoResponse, Inc.
The First Affiliated Hospital of Guangzhou Medical University
EMD Serono
Cantargia AB
Eastern Cooperative Oncology Group
Eli Lilly and Company
NextCure, Inc.
Bristol-Myers Squibb
Sir Run Run Shaw Hospital
University of California, Davis
The Netherlands Cancer Institute
Wake Forest University Health Sciences
Seagen Inc.
SciClone Pharmaceuticals
Takeda
Yonsei University
University of Alabama at Birmingham
Duke University
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Northwestern University
Telik
Abbott
Kentuckiana Cancer Institute
Hellenic Oncology Research Group
Universitair Ziekenhuis Brussel
Novacea